Clinical Trial: Efficacy and safety of sintilimab combined with platinum-based doublet chemotherapy and an adaptive radiotherapy strategy for stage III NSCLC: a single-arm, open-label, multicentre phase II clinical study (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of sintilimab combined with platinum-based doublet chemotherapy and an adaptive radiotherapy strategy for stage III NSCLC: a single-arm, open-label, multicentre phase II clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133004

Registration Time: 2026/09/20

Type: Interventional study

Primary Sponsor: The Third Xiangya Hospital Central South University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=312495

Published by HT Digital Content Services with permission from Health Daily Digest....